The clinical treatment environment for patients with EGFR-altered tumors has been revolutionized by TKI (tyrosine kinase inhibitor), a precision medicine for NSCLC (NSCLC).However, TKI (tyrosine kinase inhibitor), like all drugs, is associated with potential adverse effects, including low sodium levels, a disease characterized by low sodium levels in the blood.

The purpose of this article is to offer a detailed summary of TKI (tyrosine kinase inhibitor)-induced low sodium levels, examining its Prevalence, potential Hazard factors, manAge-related determinants-related aspects-related issues-related factors-related issues-related factors factorment strategies, and Relevance to Medical practice.I. TKI (tyrosine kinase inhibitor)-Induced low sodium levels: Prevalence and potential Hazard factorsA. prevalence rates of low sodium levels among patients receiving TKI (tyrosine kinase inhibitor)

B. potential Hazard factors associated with Onset of low sodium levels in patients Receiving TKI (tyrosine kinase inhibitor)C. The influence of Age-related determinants-related aspects-related issues-related factors-related issues-related factors factor, Sexual factors factor, and coexisting conditions on the risk of low sodium levelsII. pathological causal factors of low sodium levels Induced by TKI (tyrosine kinase inhibitor)A. causal factors underlying low sodium levels in patients Receiving TKI (tyrosine kinase inhibitor)

B. The function of ADH (anti-diuretic hormone) (ADH) and its control within hyponatremia (condition) (condition)C. The effect of osimertinib (treatment) (treatment) (treatment) (medicine) upon renal function and fluid equilibrium within hyponatremia (condition) (condition)III. Identification and Surveillance of hyponatremia (condition) (condition) (condition) Caused by osimertinib (treatment) (treatment) (treatment) (medicine)A. Clinical manifestation and diagnostic standards for recognizing hyponatremia (condition) (condition)

B. The importance of regular sodium surveillance in patients on osimertinib (treatment) (treatment) (treatment) (medicine)C. The function of laboratory exams in identifying and monitoring hyponatremia (condition) (condition)IV. hyponatremia (condition) (condition) Management Techniques Caused by osimertinib (treatment) (treatment) (treatment) (medicine)A. Non-pharmaceutical interventions for the control of hyponatremia (condition) (condition) (condition)B. Medicinal treatments for dealing with hyponatremia (condition) (condition) Caused by osimertinib (treatment) (treatment) (treatment) (medicine)

C. The function of hydration treatment and dietary modifications in the control of hyponatremia (condition) (condition) (condition)V. Clinical Implications and Future Studies Regarding hyponatremia (condition) (condition) Caused by osimertinib (treatment) (treatment) (treatment) (medicine)A. The importance of early identification and control of hyponatremia (condition) (condition) (condition) in patients on osimertinib (treatment) (treatment) (treatment) (medicine)B. The necessity for additional research to improve management techniques for hyponatremia (condition) (condition) (condition)

C. The role of medical guidelines and agreement from specialists in guiding the care of hyponatremia in patients treated with osimertinibFor clinicians managing patients with NSCLC (NSCLC), osimertinib-caused low sodium levels is a major worry.A full knowledge of the frequency, chances of occurrence, disease process, identification, and care of this condition is essential for improving patient results.

This article offers a comprehensive overview of osimertinib-caused low sodium levels, emphasizing the importance of early identification, appropriate care, and the necessity for additional studies to improve patient management.